FBT250516C139000
- 0.00
- 0.000.00%
First Trust Exchange Traded Fund Nyse Arca Biotechnology Index Fund Newsroom
Illumina Shares Are Trading Higher After Members of Management Disclosed Stock Purchases.
A Look Into Mettler-Toledo Intl Inc's Price Over Earnings
Tamboran And Daly Waters Energy Sign Binding Agreement To Finalize Checkerboard Of Joint Acreage Position Across EPs 76, 98 And 117; DWE To Buy Non-Operating, Non-Controlling Interest In 100,000 Acres For US$15M
"Don't sell if prices don't drop!" Trump enforces a mandatory minimum drug price for developed countries, but a lawsuit battle may be "reenacted".
① An executive order signed on the 12th of October, USA time, requires that the payment price of pharmaceuticals in the USA be forcibly anchored to the lowest level of other developed countries within 30 days; ② There is strong opposition within the USA, and industry experts estimate that a legal battle is about to "replay"; ③ As the market-oriented USA begins to wield the big stick of administrative pricing, the underlying rules of the game for Innovative Drugs have quietly been rewritten.
The "Most-Favored-Nation Pricing" policy for Trump Medicine has been issued: benchmarked against developed countries, complete the Quote within 30 days.
① This policy aims to align prescription drug pricing in the USA with that of "Other developed countries". Trump has requested that the Quote be completed within 30 days; ② The scope of affected Pharmaceuticals is still unclear, and the White House has stated that the government will pay special attention to drugs that have the "largest price differences and highest spending"; ③ Trump had implemented a similar policy before the end of his last term, but it was blocked by the courts and ultimately fell through.
Illumina Analysts Lower Their Forecasts After Q1 Results
Canaccord Genuity Maintains Hold on Illumina, Lowers Price Target to $87
Alnylam Pharma To Present Latest Data From Flagship Transthyretin Amyloidosis Franchise At Upcoming Heart Failure 2025 Congress
United Therapeutics Corporation Filed A Complaint On May 9, 2025, In The U.S. District Court For The Middle District Of North Carolina Against Liquidia Alleging Infringement Of U.S. Patent No. 11,357,782.
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'
ACADIA Pharmaceuticals Files For Offering Of Up To 43.6M Shares Of Common Stock By The Selling Stockholders
10 Health Care Stocks With Whale Alerts In Today's Session
Illumina Analyst Ratings
Illumina Outlines $4.18B to $4.26B Guidance for 2025 Amid China Headwinds and Strategic Cost Reductions
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Illumina Q1 Adj. EPS $0.97 Beats $0.94 Estimate, Sales $1.04B Beat $1.03B Estimate
ACADIA Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Acad Projects $244.3M Q1 Revenue With DAYBUE and NUPLAZID Growth, Anticipates Accelerated Prader-Willi Trial Data
Illumina Q1 2025 Earnings Preview
Acadia Pharma GAAP EPS of $0.11 Beats by $0.02, Revenue of $244.3M Beats by $5.33M